The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement in an all-stock transaction, allowing Alumis to leverage increased financial flexibility and an expanded late-stage ...

Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...